Richard Peck
Founder at Cellestia Biotech AG
Richard Peck active positions
| Companies | Position | Start | End |
|---|---|---|---|
Cellestia Biotech AG
 Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | Founder | 01/01/2014 | - |
| General Counsel | 01/01/2014 | - |
Career history of Richard Peck
Former positions of Richard Peck
| Companies | Position | Start | End |
|---|---|---|---|
Finox Biotech AG
 Finox Biotech AG Medical/Nursing ServicesHealth Services Finox AG specializes in developing fertility drugs. Its products include BEMFOLA, a recombinant-human follicle-stimulating hormone. The company was founded by Michel Wilhelm in 2007 and is headquartered in Burgdorf, Switzerland. | General Counsel | 01/01/2010 | - |
Statistics
International
| Switzerland | 3 |
Operational
| General Counsel | 2 |
| Founder | 1 |
Sectoral
| Health Services | 2 |
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
Finox Biotech AG
Finox Biotech AG Medical/Nursing ServicesHealth Services Finox AG specializes in developing fertility drugs. Its products include BEMFOLA, a recombinant-human follicle-stimulating hormone. The company was founded by Michel Wilhelm in 2007 and is headquartered in Burgdorf, Switzerland. | Health Services |
Cellestia Biotech AG
Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | Health Technology |
- Stock Market
- Insiders
- Richard Peck
- Experience
